AKTXAkari Therapeutics Plc

Nasdaq akaritx.com


$ 1.93 $ 0.24 (14.2 %)    

Tuesday, 04-Jun-2024 14:58:01 EDT
QQQ $ 454.82 $ 1.24 (0.27 %)
DIA $ 398.57 $ 1.27 (0.33 %)
SPY $ 530.36 $ 0.59 (0.11 %)
TLT $ 91.26 $ 1.07 (1.17 %)
GLD $ 225.37 $ -1.95 (-0.9 %)
$ 1.93
$ 1.73
$ 0.00 x 0
$ 0.00 x 0
$ 1.73 - $ 1.93
$ 1.08 - $ 5.50
55,900
na
25.96B
$ 0.96
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-29-2024 12-31-2023 10-K
3 05-12-2016 03-31-2016 10-Q
4 03-23-2016 12-31-2015 10-K
5 11-23-2015 09-30-2015 10-Q
6 08-12-2015 06-30-2015 10-Q
7 05-12-2015 03-31-2015 10-Q
8 02-11-2015 12-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 akari-therapeutics-secures-76m-in-upsized-financing-round-from-both-new-and-existing-investors

Akari Therapeutics Plc (NASDAQ:AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory d...

Core News & Articles

Prioritization of Peak's ADC cancer therapeutic platform technology and Akari's PAS-nomacopan for Geographic Atrophy, a...

 akari-therapeutics-presents-poster-on-progress-in-pre-clinical-development-of-long-acting-pas-nomacopan-as-a-potential-treatment-for-geographic-atrophy-at-the-4th-annual-dry-amd-therapeutic-development-conference

Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and infl...

 akari-therapeutics-to-present-a-poster-on-pre-clinical-development-of-long-acting-pas-nomacopan-as-a-potential-treatment-for-geographic-atrophy-at-the-4th-annual-dry-amd-therapeutic-development-conference

Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and infl...

 akari-therapeutics-h1-2023-net-loss-of-299m-versus-108m-a-year-ago-cash-balance-of-approximately-72m-sufficient-to-fund-operations-into-q1-of-2024

Akari Therapeutics (NASDAQ:AKTX) will report on H1 2023.

 akari-therapeutics-announces-existing-investors-support-the-company-through-a-2m-private-placement-financing-company-also-receives-25m-uk-rd-tax-credit

Akari Therapeutics, Plc (NASDAQ:AKTX) ("Akari" or the "Company"), a late-stage biotechnology company developing...

 akari-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement

 Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inf...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION